The online version of this article (doi:10.1186/s12891-015-0505-6) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
MDF conceived the study, participated in its design and coordination, made contributions to study implementation, and was involved in revising the manuscript critically for important intellectual content; IB participated in the design of the study, helped to draft the manuscript and performed the statistical analyses; CI participated in the design of the study, had full access to all the data in the study and takes responsibility for its integrity and the accuracy of the data analysis; MCG participated in the acquisition of data, carried out clinical evaluation and made contributions to drafting the manuscript; SF carried out laboratory tests and made contributions to data acquisition and analysis; FC performed ultrasound evaluation and participated in data analysis; GV participated in the design of the study and have been involved in revising it critically for important intellectual content, MGC conceived the study, participated in its design and coordination and have given final approval of the version to be published. All authors read and approved the final manuscript.
Vitamin D displays immunomodulatory activities and has been proposed as a potential player in the pathogenesis of rheumatoid arthritis (RA). A negative association between serum 25(OH) vitamin D levels and RA activity was demonstrated but longitudinal studies investigating the role of vitamin D levels in predicting RA activity and response to treatment are lacking. Therefore, this study was designed to test the hypothesis of an association between serum 25(OH) vitamin D levels at RA diagnosis and disease activity evaluated by clinimetric, laboratory and ultrasound (US) parameters and to detect the prevalence of remission and response to treatment after 12 months follow-up.
This is a longitudinal, retrospective study on data obtained from thirty-seven patients with early RA treatment-naïve. Serum inflammatory markers, auto-antibodies and 25(OH) vitamin D levels were obtained at baseline. Hypovitaminosis D was diagnosed for 25(OH) vitamin D levels < 20 ng/ml. Tender joint count (TJCs), swollen joint count (SJCs), Visual Analog Scales (VAS), Disease Activity Score (DAS) 28 score were assessed at baseline and 12 months after diagnosis. Joints synovitis and power-Doppler were evaluated at baseline and 12 months later.
At baseline mean 25(OH) vitamin D levels were 24.4 ± 11.9 ng/ml; 35% of study subjects had hypovitaminosis D which strongly associated with higher RA activity and lower prevalence of remission and response to treatment (all p-values < 0.001). The percentage of patients not presenting a reduction of the US synovitis score after 12 months from diagnosis was significantly higher among patients with hypovitaminosis D than in those with normal serum 25(OH) vitamin D at baseline.
In patients with early RA and basal hypovitaminosis D after 12 months follow-up reduction of disease activity and percentage of remission and response to treatment were significantly lower than those observed in patients with normal vitamin D levels. These results provide further support to the immunomodulatory action of vitamin D in RA and suggest a role of basal vitamin D status in the prediction of disease evolution. Vitamin D measurement and possibly vitamin D supplementation should be considered an additional option in the management of early RA patients.
Additional file 1: Table S1. Multivariate logistic analysis.12891_2015_505_MOESM1_ESM.docx
Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;15(423):356–61. CrossRef
Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr. 1998;128(1):68–72. PubMed
Haque UJ, Bartlett SJ. Relationships among vitamin D, disease activity, pain and disability in rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(5):745–7. PubMed
Gheita TA, Sayed S, Gheita HA, et al.: Vitamin D status in rheumatoid arthritis patients: relation to clinical manifestations, disease activity, quality of life and fibromyalgia syndrome. Int J Rheum Dis 2014 Oct 7. Epub ahead of print.
Cutolo M, Otsa K, Laas K, Yprus M, Lehtme R, Secchi ME, et al. Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin Exp Rheumatol. 2006;24(6):702–4. PubMed
Zakeri Z, Sandoughi M, Mashhadi MA, Raeesi V, Shahbakhsh S: Serum vitamin D level and disease activity in patients with recent onset rheumatoid arthritis. Int J Rheum Dis 2013 Oct 18; doi:10.1111/1756-185X.12181. [Epub ahead of print].
DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80:1689S–96. PubMed
Prevoo ML, Hof MA v ’t, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8. CrossRefPubMed
VanGestel AM, Haagsma CJ, VanRiel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41(10):1845–50. CrossRef
Wakefield RJ, Balint PV, Szkudlarek M, Filippucci E, Backhaus M, D’Agostino MA, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol. 2005;32(12):2485–7. PubMed
- Hypovitaminosis D in recent onset rheumatoid arthritis is predictive of reduced response to treatment and increased disease activity: a 12 month follow-up study
Manuela Di Franco
Maria Chiara Gerardi
Maria Gisella Cavallo
- BioMed Central
Neu im Fachgebiet Orthopädie und Unfallchirurgie
Mail Icon II